Creative Medical Technology Holdings, Inc.
CELZ Healthcare Biotechnology
Creative Medical Technology Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6,000.00, down 45.5% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 14.6% and free cash flow fell 27.1%, each against the same quarter a year earlier.
Follow CELZ
Creative Medical Technology Holdings, Inc. (CELZ) EV/Sales
As of 16 October 2026, Creative Medical Technology Holdings, Inc. (CELZ) trades at a EV/Sales of −352×. Over the past ten years it has ranged from −371× (August 2026) to 548,273× (October 2019); the current reading is higher than 0% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | −142× | — |
| FY2024 | −120× | — |
| FY2023 | −41.1× | — |
| FY2022 | −26.4× | — |
| FY2021 | −46.0× | — |
| FY2020 | 53.1× | (96.24%) |
| FY2019 | 1,412× | (93.94%) |
| FY2018 | 23,317× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2025 | −142× | — |
| Mar 2025 | −193× | — |
| Dec 2024 | −120× | — |
| Jun 2024 | −59.3× | — |
| 20 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| CELZ Creative Medical Technology Holdings, Inc. | −352× |
| CDIO Cardio Diagnostics Holdings, Inc. compare | −40.1× |
| CANF Can-Fite Biopharma Ltd compare | −8.6× |
| RVPH Reviva Pharmaceuticals Holdings, Inc. compare | n/m |
| NRSN NeuroSense Therapeutics Ltd. compare | n/m |
| BGMS Bio Green Med Solution, Inc. compare | 0.7× |
| PULM Pulmatrix, Inc. compare | 0.8× |
| IMNN Imunon, Inc. compare | 8.0× |
| ORGS Orgenesis Inc. compare | 15.7× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)